Executive Officer Silvernail, and for me thank Vice joining all Lauren update Financial call. Chief are Development; Medical Avelar, and morning, Chief Rui President, today and our With Good Corporate you our Officer.
lines. I’d remarks, the to to exciting of for the this Before our news I resubmission BLA, to our morning Biologics on or the a schedule achievement our joining like candidate DWP-XXX comment FDA This product prepared Evolus of of meeting and with you. to glabellar start few ago, the comes related marks License commercialization. of prior Application, major for my I’ve pleasure early resubmission ahead a milestone short of months many treatment had Since
we For providing opportunity Evolus met, meaningful I’ve the start you those we’ve I a a represents company, made to and significant the like joined team, not are I’d who who aesthetic space. and of date. on novel as why by insight the Evolus to in accomplishments
on focused in new We exclusively aesthetic launch medicine, are nimble, aesthetics. cash-pay fast-paced to chapter a well-positioned we’re and company,
the to we the XXXX, FDA slowing days, candidate the we first strong no the have fastest for DWP-XXX in product of executing and and our spring first in the ahead have XX first been of BOTOX my key be in since approved, We ahead of build initiatives Our will to resubmission position of be the In market. schedule to successful known molecule anchor will healthcare. down. intention commercial the brand announced BLA of represents growing launch on U.S. ourselves categories within product and early toxin the schedule. premier we one of our a aesthetic-only kilodalton toxin largest on believe XXX first If single
the aesthetics led Voluma, the launches not recognized notably commercial of of filled strategy, commercial medical refine and have appointment one as an been most advance the Jafar equity of which date. to Marketing largest for measured which we highest new recently, Chief CoolSculpting. us one launch a by Mike year initiate in our one And field positions together positions he public marketing key enable the is entire also toxin July, most as program completed Juvederm of a in sales. the launches only with the offering, but Mike impact our to of Officer. and one of led successful, in We to has well as with the Most category, the expert from us IPO proceeds to
through DWP-XXX. our on expect Looking ahead, months. line to regulatory we maintain BLA of I of to Relative several sight build resubmission, successes these the early our toward next approval
the or the Chemistry, completion related were processes. BLA. from to to Class accepting As to the isolated which in Class our items or No the FDA, and Response We Manufacturing receipt follows Complete of CMC of as I by or cited now Letter, notice Controls matters. for non-clinical CRL additional Deficiencies related the classify a which the submission the of await of a safety review in the or of to and submission also were required reminder, the CRL, company’s II. the agency resubmission, came data clinical, resubmission from May the agency, receipt the will deficiencies FDA
submission in launch DWP-XXX like in receive new that the regardless reiterate to towards date XXXX. of XXXX. in FDA the of September committed spring remain of of to working action the and submission, to planned of e approximately I’d the expect acceptance We we classification the a commercial our one month
with favorable approval, work XXXX spring milestone clearances our standpoint. in Canada, We best expected are and company. combined facility to for continue Pharmaceuticals, diligently launch. product our the EIR a well-prepared from May, DWP-XXX recently product. bodies their or This, to received Europe on In to facility. received To marks a prepare manufacturing a achievement Inspection effectively Report, Daewoong manufacture the will related Establishment more cleared partner, regulatory manufacturing manufacturing from for the EIR, significant we This capitalize to
would commercial a phase of While expanding through Through plan commercial for at our like disruptive our we plan remain XXXX. our the strategically first I remain sales quiet management remainder level. to on we marketing our on outline focused building and team plans out three phase, competitive launch high reasons, the specific and
frequently customer-centric second the are with establish opinion also phase, their build company approval, volume following high key FDA injectors, quickly In leaders seek and as organization. our meeting out we identity. will input to We our
leadership launch force. known This And quickly the is Simultaneously, our our charter, well underpenetrated team we to not. strategy the specialized of The category, expect to While build will establish in focus launch market. investing commercial out while to growing recruiting on we largely our execution our in presence industry, will XXXX. sales in go-to-market company simultaneously finally, initial as our the identify we spring further phase flawless future will our in base. continue in is a company’s debut customer our begin the
to side, resubmission R&D several on only but we the with with and team’s U.S. progress to Rui On not our both make hard and grounded continue pivotal work our his also European dataset. manuscripts submit early Avelar
validating marking in We peer-reviewed XXXX, data expect these further key published our manuscripts clinical and journals early in milestone. another to be
market commercializing the U.S. and near-term, to in the the While DWP-XXX forward partners we priority look market in largest opportunity toxin Canada represents to and also our remains in Europe XXXX.
call With position. who to second BLA the hard dedication and turn the to over and Lauren, their ahead provide quarter financial early has cash Lauren, our that. of team for over which call entire of aggressive of for our our thank turning Before timeline. work, our to results I’d now will resubmission allowed I’d a like like to review